IRF3 and severe acute respiratory syndrome: The need for IFN antagonists to reach a threshold level before becoming effective is illustrated by the observation that at an early time point during SARS-CoV infection, IRF3 is observed to translocate to the nucleus whereas it is excluded from the nucleus at a later time point [38].